title: [Combined therapy of acromegaly with a combination of lanreotide and terguride].
abstract: BACKGROUND
  The aim of the treatment of acromegaly is to normalise the hormonal activity. Besides the surgical and radiation treatment, medical therapy can be used. The project was set to determine the value of combined therapy with lanreotide and terguride in patients with active acromegaly.
  
  
  RESULTS
  Nine patients previously treated with lanreotide for at least one year without normalisation of hormonal activity were included in the study. Terguride was added to lanreotide for one month. The combined treatment brought about reduction of growth hormone (GH) levels, however, with marginal significance only. GH-BP, IGF-I and IGFBP-3 serum levels were not changed significantly. Considering the individual cases, the combined treatment resulted in normalisation of GH levels in one patient and that of IGF-I in another one. Substantial decrease of GH levels (> 50%) was found in three patients and that of IGF-I (> 20%) in another one patient.
  
  
  CONCLUSIONS
  The combined treatment of acromegaly appears to be more effective than monotherapy with lanreotide only in a subset of acromegalic patients.
authors.affiliation: III. interní klinika 1. LF UK a VFN, Praha. mkrse@lf1.cuni.cz
authors.forename: M
authors.initials: M
authors.lastname: Krsek
authors.forename: V
authors.initials: V
authors.lastname: Hána
authors.forename: J
authors.initials: J
authors.lastname: Marek
authors.forename: V
authors.initials: V
authors.lastname: Justová
authors.forename: Z
authors.initials: Z
authors.lastname: Lacinová
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D002352:Carrier Proteins / Q000097:blood; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008090:Lisuride / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D013004:Somatostatin / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D002352:Carrier Proteins; D018491:Dopamine Agonists; D018972:Insulin-Like Growth Factor Binding Protein 3; D010456:Peptides, Cyclic; C060347:lanreotide; C006208:dironyl; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D008090:Lisuride; C051815:somatotropin-binding protein